Prosecution Insights
Prosecution Insights
13 pending office actions • 12 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (46%) |
| §112 only | 3 (23%) |
| Double-patenting + other | 2 (15%) |
| No statute on record | 2 (15%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAUNER, JOSEPH G | 1 | 56.8% | +34.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.2% |
| CANELLA, KAREN A | 1 | 62.6% | +32.9% |
| SUNSHINE, HANNAH LOUISE | 1 | 71.0% | +13.3% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 54.2% | +73.3% |
| STOICA, ELLY GERALD | 1 | 66.5% | +22.9% |
| GRABER, JAMES J | 1 | 46.2% | +56.1% |
| FORD, VANESSA L | 1 | 40.1% | +38.3% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.6% | +42.1% |
| BAILEY, STEVEN WILLIAM | 1 | 34.8% | +20.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774464 | METHODS OF DETERMINING ATTRIBUTES OF THERAPEUTIC T CELL COMPOSITIONS | BAILEY, STEVEN WILLIAM | 71d overdue |
| 17850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 31d overdue |
| 17799239 | BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF | GRABER, JAMES J | 18d overdue |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | SUNSHINE, HANNAH LOUISE | 8d overdue |
| 17917923 | METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN | STOICA, ELLY GERALD | 2d overdue |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | JOHNSON, CHRISTOPHER LINDSAY | 26d |
| 17794245 | METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY | FORD, VANESSA L | 41d |
| 18488850 | EPIGENETIC ANALYSIS OF CELL THERAPY AND RELATED METHODS | DAUNER, JOSEPH G | 47d |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1682 | 1 |
| 1625 | 1 |
| 1643 | 1 |
| 1691 | 1 |
| 1631 | 1 |
| 1674 | 1 |
| 1634 | 1 |
| 1687 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18488850 | EPIGENETIC ANALYSIS OF CELL THERAPY AND RELATED METHODS | DAUNER, JOSEPH G | 1682 | §103 | Final Rejection | 47d | Pending | Oct 17, 2023 |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 1625 | DPOther | Non-Final OA | 70d | Pending | May 03, 2023 |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 1643 | DPOther | Non-Final OA | 63d | Pending | Mar 22, 2023 |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | SUNSHINE, HANNAH LOUISE | 1647 | §112 | Non-Final OA | 8d overdue | Pending | Feb 02, 2023 |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Final Rejection | 26d | Pending | Oct 26, 2022 |
| 17917923 | METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN | STOICA, ELLY GERALD | 1647 | §103 | Non-Final OA | 2d overdue | Pending | Oct 07, 2022 |
| 17799239 | BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF | GRABER, JAMES J | 1631 | Other | Non-Final OA | 18d overdue | Pending | Aug 11, 2022 |
| 17794245 | METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY | FORD, VANESSA L | 1674 | §112 | Final Rejection | 41d | Pending | Jul 20, 2022 |
| 17850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | 31d overdue | Pending | Jun 27, 2022 |
| 17774464 | METHODS OF DETERMINING ATTRIBUTES OF THERAPEUTIC T CELL COMPOSITIONS | BAILEY, STEVEN WILLIAM | 1687 | §103 | Non-Final OA | 71d overdue | Pending | May 04, 2022 |
| 17291536 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | VAN BUREN, LAUREN K | 1638 | Other | Non-Final OA | 19d | Pending | May 05, 2021 |
| 17266995 | METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS | ZAHORIK, AMANDA MARY | 1636 | §103 | Non-Final OA | 27d | Pending | Feb 08, 2021 |
| 16634497 | REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS | KIM, YUNSOO | 1641 | §112 | Non-Final OA | 24d overdue | Pending | Jan 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial